A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof

Future Oncol. 2015;11(9):1421-8. doi: 10.2217/fon.15.3. Epub 2015 Jan 20.

Abstract

The management of colorectal liver metastasis has undergone a significant change since the development of novel ablation and embolization. Drug-eluting microsphere platforms, designed to deliver targeted concentrations of systemic therapy directly into the tumor via its arterial vasculature, have garnered interest and gained in popularity in recent years. Based on in vitro and in vivo data, multiple factors contribute to locoregional exposure including carrier base, smaller particle size (larger surface area), chemotherapeutic and chemotherapeutic intensity. Based on the current published clinical data, therapy appears well tolerated but the questions remain as to the ideal technique, patient population and overall efficacy. The purpose of this article is to provide a perspective on the scientific basis, and clinical review of the current data supporting the use of this platform in the setting of metastatic colorectal carcinoma.

Keywords: DEBIRI; colon cancer metastasis; colorectal liver metastasis; drug-eluting bead; embolization; interventional radiology; irinotecan drug-eluting beads; liver-directed therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Chemoembolization, Therapeutic* / methods
  • Clinical Trials as Topic
  • Colorectal Neoplasms / pathology*
  • Drug Carriers
  • Drug Delivery Systems
  • Humans
  • Liver Neoplasms / mortality
  • Liver Neoplasms / secondary*
  • Liver Neoplasms / therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Drug Carriers